PRKCZ

Across TCGA pan-cancer cohorts, PRKCZ Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRKCZ data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher PRKCZ Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRKCZ expression acts as an unfavorable survival marker, although some lineages such as SCLC show a favorable association.

DLBC, UCEC, and PRAD are the cancer types where PRKCZ Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.118	0.802	.025	12	view →
UCEC	OS	Median	IV	0.225	0.772	<.001	12	view →
PRAD	DFS	Median	All	0.617	0.886	.049	6	view →
LUSC	OS	Median	All	0.307	0.728	.028	6	view →
SCLC	DFS	Median	All	1.000	0.261	.026	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRKCZ–DLBC (OS)

Open the DLBC breakdown →